

RECEIVED
CENTRAL FAX CENTER

OCT 25 2005



GlaxoSmithKline

FAX**To** Attn: Examiner David Paul STITZEL, Group 8793**Company** USPTO**Fax** 571-273-8300**From** Andrea N. Scoggins**Tel** 1-919-483-9552; Facsimile: 1-919-483-7977**E-mail** andrea.n.scoggins@gsk.com**Date** October 25, 2005 **Pages including cover** 4**Subject** Response to Restriction RequirementGlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709Tel: 919 483 2100
www.gsk.com

Re: Application of Christopher Charles ABNEY et al
U.S. Serial No.: 10/619,766 Filed: July 15, 2003
Title: *Pharmaceutical compositions for oral
Administration comprising lithium carbonate,
Processes of making the same, and methods of
Administering the same.*
Attorney Docket No.: PR60153US

Attached:

1. Transmittal Form with Certificate of Transmission/Mailing
2. Response to Restriction Requirement (2 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

OCT 25 2005

Doc

PTO/SB/21 (09-04)


Approved for use through 07/31/2008. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/619,766
	Filing Date	July 15, 2003
	First Named Inventor	Christopher Charles ABNEY et al.
	Art Unit	8793
	Examiner Name	David Paul STITZEL
Total Number of Pages in This Submission	Attorney Docket Number	PR60153US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Applicants believe that no fee is required for this submission. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	GlaxoSmithKline		
Signature			
Printed name	Robert J. Smith		
Date	October 25, 2005	Reg. No.	40,820

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the			
Signature			
Typed or printed name	Andrea N. Scoggins	Date	October 25, 2005

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Atty. Docket No.: PR60153US

OCT 25 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Christopher Charles ABNEY et al.
Appl. No. : 10/619,766
Filed : July 15, 2003
Title : *Pharmaceutical compositions for oral
Administration comprising lithium carbonate,
Processes of making the same, and methods of
Administering the same.*
Group A/U. : 8793
Examiner : David Paul STITZEL
Docket : PR60153US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION

Sir:

This paper is submitted in response to the Office Action mailed 10/07/2005 for which a 1 month shortened statutory period to respond was set. Accordingly, this paper is timely filed on or before 11/07/2005. Early examination of the application on the merits is earnestly solicited.